Shanghai Kehua Bio-engineering Bundle
What's the story behind Kehua Bio's rise in the Chinese biotech scene?
Founded in 1981, Shanghai Kehua Bio-engineering Company (Kehua Bio) has become a prominent name in the in vitro diagnostics (IVD) industry. This Chinese biotech pioneer initially made waves with groundbreaking ELISA reagents, setting the stage for its current status as a high-tech enterprise. Discover how Kehua Bio's commitment to innovation has shaped its journey.
From its early days, Kehua Bio has demonstrated a strong focus on research and development. Today, with a market capitalization of $432 million and a vast product portfolio, including over 100 diagnostic instruments and 700 reagents, Kehua Bio continues to expand its global footprint. For a deeper dive into Kehua Bio's strategic position, consider reviewing a comprehensive Shanghai Kehua Bio-engineering SWOT Analysis.
What is the Shanghai Kehua Bio-engineering Founding Story?
The founding of Shanghai Kehua Bio-engineering Company, often referred to as Kehua Bio, marked a significant step in the development of China's bio-engineering sector. Established on November 22, 1981, in Shanghai, the company set out to become a key player in the in vitro diagnostic (IVD) market.
Kehua Bio's early focus was on meeting the growing need for advanced diagnostic solutions within China. This strategic positioning allowed the company to capitalize on the increasing demand from hospitals and medical institutions across the country. The company's initial focus on research and development was critical to its early success.
The company's early achievements included the launch of the first ELISA reagents for hepatitis B and C, as well as dual-liquid clinical chemistry reagents in China. Kehua Bio also obtained the first drug license in China for blood nucleic acid screening products. These achievements highlighted the company's commitment to innovation from the start. For more details, you can read about the Mission, Vision & Core Values of Shanghai Kehua Bio-engineering.
Key Milestones in the Founding Story
The establishment of Kehua Bio in 1981 was a pivotal moment in the history of Chinese biotech.
- November 22, 1981: Kehua Bio was founded in Shanghai.
- Early Focus: Developing and marketing in vitro diagnostic (IVD) products.
- Key Products: Pioneering ELISA reagents for hepatitis B and C, and dual-liquid clinical chemistry reagents.
- Strategic Positioning: Addressing the growing demand for clinical testing solutions in China.
Shanghai Kehua Bio-engineering SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Shanghai Kehua Bio-engineering?
The early growth of Shanghai Kehua Bio-engineering Company, often referred to as Kehua Bio, was marked by rapid expansion within the in vitro diagnostics (IVD) market. A significant step was its listing on the Shenzhen Stock Exchange in 2004, making it the first publicly listed company in China's IVD sector. This strategic move provided crucial capital for further development, solidifying its position in the domestic market and setting the stage for future growth.
Geographical Expansion
Kehua Bio expanded its operational footprint by establishing R&D and manufacturing bases in various locations. These included Xi'an, Suzhou, and the Greater Bay Area, as well as facilities in Italy and South Korea. This expansion strategy facilitated both geographical growth and the diversification of its product categories, enhancing its market reach and operational capabilities.
Product Portfolio Development
The company's product line evolved to cover five key areas: immunodiagnostics, clinical chemistry, molecular diagnostics, mass spectrometry, and point-of-care testing (POCT). This comprehensive approach allowed Kehua Bio to offer integrated solutions, combining reagents, instruments, and services. Further insights into the company's business model can be found in Revenue Streams & Business Model of Shanghai Kehua Bio-engineering.
Key Product Launches and Innovations
Early product launches included ELISA reagents for hepatitis B and C, and dual-liquid clinical chemistry reagents. Kehua Bio also made strides in nucleic acid screening products, securing the first drug license in China for such products. This commitment to innovation resulted in a robust portfolio, featuring over 100 self-developed diagnostic instruments and more than 700 diagnostic reagents.
Market Presence and International Recognition
Kehua Bio established a significant domestic marketing network, with its products exported to over 100 countries and regions. Its AIDS diagnostic reagents were included in the procurement catalogs of international organizations such as the World Health Organization (WHO), UNICEF, and the U.S. Presidential Fund. The company also secured a long-term supply contract with the U.S. Clinton Foundation.
Shanghai Kehua Bio-engineering PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Shanghai Kehua Bio-engineering history?
The Shanghai Kehua Bio-engineering Company, also known as Kehua Bio, has marked several significant milestones throughout its history. A key achievement was becoming the first publicly listed company in China's in vitro diagnostics (IVD) industry in 2004, solidifying its position in the bio-engineering sector. This early success set the stage for future growth and innovation, shaping the Company History of Kehua.
| Year | Milestone |
|---|---|
| 2004 | Became the first publicly listed company in China's IVD industry. |
| 2019 | Launched Polaris, a biochemical and immunological analysis system. |
| October 2023 | Obtained EU Class D IVDR certification for its rapid test HIV colloidal gold diagnostic kit. |
| April 2024 | Biological reference laboratory received approval from CNAS for cholesterol and 25-hydroxyvitamin D3 projects. |
| February 2025 | Reference Laboratory has a total of 11 projects on the JCTLM Medical Reference Measurement List. |
Kehua Bio has consistently invested in research and development, leading to numerous innovations in the IVD field. These innovations include pioneering the first ELISA reagents for hepatitis B and hepatitis C in China, as well as dual-liquid clinical chemistry reagents. The company's commitment to innovation is evident in its diverse product range and its ability to adapt to market demands.
First ELISA Reagents
Pioneered the first ELISA reagents for hepatitis B and hepatitis C in China.
Dual-Liquid Reagents
Developed dual-liquid clinical chemistry reagents.
Blood Nucleic Acid Screening
Secured the first drug license in China for blood nucleic acid screening products.
Polaris System
Launched Polaris, a biochemical and immunological analysis system with independent intellectual property rights in 2019.
EU Class D IVDR Certification
Obtained EU Class D IVDR certification for its rapid test HIV colloidal gold diagnostic kit in October 2023.
Reference Laboratory Approval
The company's biological reference laboratory received approval from the China National Accreditation Service (CNAS) for projects related to cholesterol and 25-hydroxyvitamin D3 in April 2024.
Despite its achievements, Kehua Bio has faced financial challenges, with a net loss of CNY 640.6 million for the full year ended December 31, 2024. This represents a significant increase compared to the net loss of CNY 234.01 million in 2023, indicating the impact of market dynamics and competitive pressures. For more information about the competitive environment, you can read about the competitors landscape of Shanghai Kehua Bio-engineering.
Financial Performance in 2024
Reported a net loss of CNY 640.6 million for the full year ended December 31, 2024.
This represents a 173.7% increase in losses compared to the previous year.
Revenue Decline in 2024
Revenue for 2024 was CNY 1,759.2 million.
This is a decrease of -27.55% compared to CNY 2,428.08 million in the previous year.
Net Income Margin
The net income margin for the year ending December 31, 2024, was -36.41%.
Continued Investment
Despite financial challenges, KHB continues to invest in R&D.
The company focuses on integrating reagents and instruments and expanding its product lines.
Strategic Partnerships
Engages in strategic partnerships with international IVD enterprises.
These partnerships foster collaborative innovation and technology co-development.
Honors and Awards
The company has received honors such as the National Science and Technology Progress Award (Second Class).
Also recognized as a National Intellectual Property Demonstration Enterprise.
Shanghai Kehua Bio-engineering Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Shanghai Kehua Bio-engineering?
The Owners & Shareholders of Shanghai Kehua Bio-engineering have steered the company through significant milestones, beginning with its establishment in 1981. Key events include pioneering ELISA reagents in the early 1990s, becoming the first IVD company listed on the Shenzhen Stock Exchange in 2004, and exporting HIV test kits through the Clinton Foundation from 2007. More recent achievements include the 2019 launch of the Polaris analysis system and obtaining EU Class D IVDR certification in October 2023.
| Year | Key Event |
|---|---|
| 1981 | Shanghai Kehua Bio-engineering Co., Ltd. (KHB) is established in Shanghai, China. |
| Early 1990s | KHB pioneers the launch of the first ELISA reagents for hepatitis B and hepatitis C in China. |
| 2004 | KHB is listed on the Shenzhen Stock Exchange (stock code: 002022.SZ), becoming the first publicly listed company in China's in vitro diagnostics (IVD) industry. |
| 2007 | KHB begins exporting HIV test kits through the Clinton Foundation. |
| 2019 | KHB launches Polaris, a biochemical and immunological analysis system with independent intellectual property rights. |
| 2023 (October) | KHB becomes the first Chinese company to obtain EU Class D IVDR certification for its rapid test HIV colloidal gold diagnostic kit. |
| 2023 (December) | Kehua Biotech enters into contracts/agreements related to its operations. |
| 2024 (April) | The company's biological reference laboratory receives approval from the China National Accreditation Service (CNAS) for a project related to cholesterol and 25-hydroxyvitamin D3. |
| 2024 (December) | Shanghai Kehua Bio-Engineering reports full-year sales of CNY 1,759.2 million and a net loss of CNY 640.6 million. |
| 2024 (September 5) | Shanghai Kehua Biological Engineering's most recent deal is an Early Stage VC with ArrayHope. |
| 2025 (January) | KHB holds its 2024 Awards Ceremony and Annual Gala, reflecting on achievements and looking ahead to 2025. |
| 2025 (February) | KHB participates in Medlab Middle East 2025, showcasing cutting-edge solutions for human and veterinary diagnostics. |
| 2025 (February) | KHB Reference Laboratory's Measurement Traceability Service expands globally, with a total of 11 projects on the JCTLM Medical Reference Measurement List. |
| 2025 (February) | KHB announces participation in CACLP 2025. |
| 2025 (March 31) | Shanghai Kehua Biological Engineering has a trailing 12-month revenue of $236M. |
| 2025 (May 20) | Shanghai Kehua Biological Engineering's stock price is $0.84, with a market cap of $432M. |
Innovation and R&D
Kehua Bio is committed to continuous innovation, building upon its established technology platforms for clinical IVD reagents and fully automatic detection and analysis instruments. The company is focusing on advancing precision medicine.
Market Expansion
The company aims to expand its presence in the global IVD industry, actively participating in major industry events like Medlab Middle East 2025 and CACLP 2025 to showcase its innovations. The company is also expanding its reference laboratory services.
Strategic Partnerships
Kehua Bio is focused on forming strategic partnerships to enhance its market position. The company is exploring new opportunities for collaboration.
Financial Performance and Outlook
Despite a net loss of CNY 640.6 million in 2024, the company is looking forward to the future with passion and commitment. Trailing 12-month revenue is $236M as of March 31, 2025, and the market cap is $432M as of May 20, 2025.
Shanghai Kehua Bio-engineering Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What is Competitive Landscape of Shanghai Kehua Bio-engineering Company?
- What is Growth Strategy and Future Prospects of Shanghai Kehua Bio-engineering Company?
- How Does Shanghai Kehua Bio-engineering Company Work?
- What is Sales and Marketing Strategy of Shanghai Kehua Bio-engineering Company?
- What is Brief History of Shanghai Kehua Bio-engineering Company?
- Who Owns Shanghai Kehua Bio-engineering Company?
- What is Customer Demographics and Target Market of Shanghai Kehua Bio-engineering Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.